List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
A new study has shown that lactate, a metabolic byproduct produced during exercise, could augment current cancer immunotherapies.
Researchers have revealed the immune landscape and microbiome of pancreatic cysts as they progress to pancreatic cancer, providing targets for immunotherapy.
Scientists have discovered adenosine could inhibit CD39, a molecule that suppresses the immune system.
Researchers have discovered a way to ignite T cells, potentially increasing the scope and success of T cell-based immunotherapy.
Scientists have found that unconventional T cells migrate from tissue into the lymph nodes and influence immune responses there.
An animal study has shown that a modified vaccine for tuberculosis could treat bladder cancer whilst minimising side effects.
Researchers found that fibroblasts had varying effects on tumour cells based on both the type of non-small cell lung cancer and the drug used for treatment.
Researchers have developed an mRNA-based cancer vaccine that is delivered directly into the lymphatic system for a more potent response.
The researchers identified key molecular differences between triple-negative breast cancer cells that cling to an initial tumour and those that venture off to form distant tumours.
The monoclonal antibody 19A11 binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.
New study has demonstrated that mice deficient in dendritic cell immunoreceptor are resilient against colitis and colonic tumour growth.
A T-cell bispecific antibody shows potent anti-tumour activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma.
